In Vitro Hemolysis Rate Quantitative Testing: Principles, Standards, Methods, and Applications for M

In vitro hemolysis rate quantitative testing is a fundamental hemocompatibility assay that measures the degree of red blood cell lysis caused by blood-contacting medical devices, biomaterials, and their extracts. Performed in accordance with ISO 10993-4, GB/T 16886.4, and ASTM F756, this spectrophotometric test is a mandatory biocompatibility item for regulatory submissions of blood-contacting products worldwide. This article provides a comprehensive technical overview of the test principle, sample types, methodologies, calculation, acceptance criteria, and practical applications.

Technical Overview

In vitro hemolysis rate quantitative testing determines, in a quantitative manner, the extent to which a medical device, biomaterial, or its extract induces lysis (rupture) of red blood cells. When erythrocytes are damaged by physical surface effects, leached chemical substances, or shear forces, intracellular hemoglobin is released into the surrounding medium. By measuring the free hemoglobin concentration in the supernatant spectrophotometrically at approximately 540 to 545 nm and comparing it against fully lysed (positive) and non-lysing (negative) controls, the hemolysis rate can be calculated as a percentage.

Hemolysis testing is a core element of the blood interaction evaluation required by ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood) and its Chinese equivalent GB/T 16886.4, where it falls under the hematology category of hemocompatibility assessment. In the United States and many other markets, ASTM F756 (Standard Practice for Assessment of Hemolytic Properties of Materials) is widely applied. Sample preparation follows ISO 10993-12 and GB/T 16886.12, which define extraction ratios, solvents, and conditioning conditions.

The hemolysis rate is calculated using the following general equation:

• Hemolysis rate (%) = (A(test) − A(negative control)) / (A(positive control) − A(negative control)) × 100

where A represents the absorbance of the supernatant at the measurement wavelength. A result below 5% is generally accepted as indicating a non-hemolytic material for regulatory purposes, while ASTM F756 further classifies materials as non-hemolytic (approximately 2% or less), slightly hemolytic (approximately 2% to 5%), and hemolytic (greater than 5%).

Testing Samples

Finished Blood-Contacting Medical Devices

Any device that contacts circulating blood directly or indirectly is a candidate for hemolysis testing. Typical submissions include:

• Intravenous catheters, cannulas, and infusion sets
• Syringes, hypodermic needles, and blood collection tubes
• Blood bags, transfusion sets, and blood filters
• Hemodialyzers, hemoperfusion cartridges, and extracorporeal circulation circuits
• Oxygenators, ECMO tubing, and blood pumps
• Vascular stents, grafts, heart valves, and vena cava filters
• Guidewires, introducer sheaths, and interventional accessories

Raw Biomaterials and Coatings

During material development and screening, polymer films, sheets, tubing segments, metal alloys, ceramics, hydrogel coatings, antithrombotic or surface-modified layers, and biodegradable scaffolds are evaluated to characterize their hemolytic potential before device integration.

Extracts and Process-Related Substances

Aqueous extracts prepared from devices or materials, as well as residual processing chemicals, sterilization residues, cleaning agents, extractables and leachables, and packaging materials that contact blood products, can be quantitatively assessed.

Emerging Materials

Nanomaterials, liposomes, drug delivery carriers, and pharmaceutical excipients intended for intravascular administration are increasingly evaluated using the same quantitative hemolysis methodology.

Testing Items

The quantitative hemolysis test package typically includes the following measurable items:

• Quantitative hemolysis rate of the test sample or extract, expressed as a percentage
• Absorbance of the test, positive control, and negative control supernatants at 540–545 nm
• Free hemoglobin concentration released into the test medium
• Validation of positive control (sterile distilled or deionized water) and negative control (physiological saline or phosphate-buffered saline) performance
• Assessment of test validity, for example a low negative-control absorbance and near-complete lysis in the positive control
• Optional complementary hemocompatibility endpoints such as plasma free hemoglobin, complement activation, thrombogenicity, coagulation, and platelet function, as part of a broader ISO 10993-4 evaluation

Testing is normally performed with replicate samples to ensure statistical robustness, and all procedures are executed under aseptic conditions in accredited third-party laboratories or in-house biocompatibility facilities.

Testing Methods

Sample Preparation and Controls

Test samples are prepared and sterilized in the same condition as intended for clinical use. Extraction is performed with physiological saline or another justified vehicle at standardized surface-area-to-volume or mass-to-volume ratios, followed by conditioning such as 37°C for 24 hours or another validated regime in accordance with ISO 10993-12. Fresh anticoagulated rabbit blood or human donor blood is diluted, and every assay run includes a positive control and a negative control to verify system suitability.

Indirect Contact (Extraction) Method

In the indirect method, the test extract is mixed with a defined volume of diluted fresh anticoagulated blood and incubated at 37 ± 1°C for a protocol-defined period, commonly ranging from 60 minutes to several hours. This approach is appropriate for devices that contact blood indirectly, for leachable substances, and for materials where direct physical contact is impractical.

Direct Contact Method

In the direct contact method, the test article itself is placed in contact with diluted blood under static conditions, typically at 37 ± 1°C for a defined incubation time. This method evaluates both chemical leachables and surface-mediated mechanical damage to erythrocytes, and it is suitable for surface-communicating materials and finished device configurations.

Dynamic Method for Blood-Handling Devices

For devices designed to handle flowing blood, such as blood pumps, oxygenators, dialysis circuits, and ECMO systems, a dynamic recirculation test exposes blood to the device under controlled flow and shear conditions that simulate clinical use. This method captures hemolysis induced by hydrodynamic shear in addition to material effects.

Measurement and Calculation

Following incubation, samples are centrifuged to sediment intact erythrocytes, for example approximately five minutes at 800 to 1000 × g. The absorbance of the resulting supernatant is measured by UV-visible spectrophotometry at approximately 545 nm, the absorption region of free hemoglobin. The hemolysis rate of each sample is then calculated using the standard equation referenced above, and replicate values are averaged.

Result Interpretation

A hemolysis rate below 5% is widely accepted, including in submissions aligned with GB/T 16886.4, as demonstrating that the device is non-hemolytic. Under the ASTM F756 classification scheme, results are graded as non-hemolytic, slightly hemolytic, or hemolytic based on the percentages noted earlier. Results exceeding acceptance limits typically trigger material reformulation, surface modification, process optimization, or a documented risk justification.

Applications

Regulatory Registration and Market Access

Quantitative hemolysis data are required or expected for registration of blood-contacting devices in major jurisdictions, including national medical device market applications, premarket notifications, and conformity assessment under regional regulations in Europe and elsewhere. The test report, issued by accredited third-party laboratories, forms part of the biocompatibility documentation for the device master file or technical file.

Research and Development

Material scientists use hemolysis screening as a fast, sensitive indicator of blood compatibility during candidate selection, coating development, sterilization validation, and formulation refinement, allowing early elimination of hemolytic materials before costly device-level testing.

Quality Control and Batch Release

For high-risk blood-handling products such as oxygenators, dialyzers, and extracorporeal circuits, hemolysis testing supports routine quality control, change control, and periodic verification of manufacturing consistency.

Scientific Research and Publication

Academic studies of biomaterials, nanomedicines, and blood-contacting surfaces routinely report quantitative hemolysis rates as a standard biocompatibility metric supporting publication and translation.

FAQ

Question: What hemolysis rate is considered acceptable?

Answer: A hemolysis rate below 5% is generally accepted as evidence that the sample is non-hemolytic for regulatory purposes, consistent with criteria commonly applied alongside GB/T 16886.4. ASTM F756 further distinguishes materials as non-hemolytic at approximately 2% or less and slightly hemolytic between approximately 2% and 5%, with values above 5% classified as hemolytic.

Question: Which standards govern in vitro hemolysis testing?

Answer: The principal standards are ISO 10993-4 and GB/T 16886.4 for blood interaction evaluation, ASTM F756 for assessment of hemolytic properties of materials, and ISO 10993-12 together with GB/T 16886.12 for sample preparation. Historical method standards for infusion and transfusion equipment are also referenced in many test protocols.

Question: What type of blood is used in the test?

Answer: Fresh anticoagulated rabbit blood is most commonly used in routine testing, while fresh human donor blood may be used with justification. Anticoagulation is achieved with heparin, sodium citrate, or acid-citrate-dextrose, and the blood is diluted to a defined hematocrit and used within a validated time window after collection.

Question: How do I choose between the direct contact, extraction, and dynamic methods?

Answer: The method is selected based on the nature of blood contact anticipated in clinical use. Indirect extraction suits devices and materials whose leachables contact blood, direct contact suits surface-communicating materials and device geometries, and dynamic testing is appropriate for devices that actively pump, oxygenate, or recirculate blood under shear conditions.

Question: How much sample is required and what is the typical turnaround time?

Answer: Sample requirements depend on the method and extraction ratio; typically, complete sterile devices or a specified mass or surface area of material is needed, along with replicate samples. Turnaround time in accredited third-party laboratories is commonly five to ten working days after sample receipt, subject to protocol confirmation and test scheduling.

Question: Can hemolysis testing replace a full hemocompatibility evaluation?

Answer: No. Hemolysis testing addresses only the hematology endpoint of ISO 10993-4. Depending on the device category and blood contact duration and conditions, a complete hemocompatibility panel may also include thrombosis, coagulation, platelet, and complement activation tests, selected through a documented risk-based rationale.